Business Context and Reporting Period
Syndax Pharmaceuticals, Inc. (SNDX) is a commercial-stage biopharmaceutical company focused on developing cancer therapies. The company reported for the quarterly period ended September 30, 2024. Its primary commercial asset is NIKTIMVO® (axatilimab-csfr), approved by the FDA in August 2024 for chronic graft versus host disease (cGVHD), with a U.S. launch anticipated in early Q1 2025. Its lead product candidate, revumenib, is under Priority Review by the FDA for acute leukemias with a PDUFA target date of December 26, 2024.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $12,500 | $0 | $16,000 | $0 |
| Net Loss | $(84,126) | $(51,146) | $(224,589) | $(136,887) |
| Net Loss Per Share (Basic/Diluted) | $(0.98) | $(0.73) | $(2.63) | $(1.97) |
| Operating Expenses | $102,077 | $56,355 | $259,307 | $152,049 |
| Cash, Cash Equivalents & Investments | $399,636 | $600,527 | $399,636 | $600,527 |
| Accumulated Deficit | $(1,126,989) | $(829,927) | $(1,126,989) | $(829,927) |
Note: Revenue consists entirely of milestone and license fees; there were no product sales.
Material Changes vs. Prior Period
- Revenue Recognition: The company recognized $12.5 million in Q3 2024 milestone revenue following FDA approval of Niktimvo. This compares to zero revenue in Q3 2023. For the nine months ended September 30, 2024, total revenue was $16.0 million, including a $3.5 million milestone from Eddingpharm recognized in Q2.
- Expense Growth: Operating expenses increased significantly, driven by R&D and SG&A. R&D expenses rose to $70.97 million in Q3 2024 from $39.09 million in Q3 2023, primarily due to registrational trial costs for revumenib, pre-commercial manufacturing, and a $15.0 million milestone payment to UCB for Niktimvo approval. SG&A expenses increased to $31.11 million from $17.27 million due to commercial readiness activities.
- Liquidity Position: Cash, cash equivalents, and investments decreased from $600.5 million at year-end 2023 to $399.6 million at September 30, 2024, reflecting a net cash burn of $217.5 million from operating activities over the nine-month period.
Guidance, Outlook, and Risks
- Regulatory Milestones: The FDA PDUFA date for revumenib is December 26, 2024. Topline data for the AUGMENT-101 trial in mNPM1 AML is expected in Q4 2024.
- Commercialization: Niktimvo is expected to launch in the U.S. no later than early Q1 2025, co-commercialized with Incyte.
- Capital Resources: Management believes current cash and investments will fund operations for at least the next 12 months. In October 2024 (subsequent to the reporting period), the company entered a royalty monetization agreement with Royalty Pharma, receiving a $350 million upfront payment in exchange for 13.8% of U.S. net sales of Niktimvo.
- Risks: Key risks include the uncertainty of regulatory approval for revumenib, the ability to successfully launch and gain market acceptance for Niktimvo, reliance on third-party manufacturers, and the need for additional capital to fund future operations.
Investor Verification Checklist
- Revumenib Approval Status: Verify the outcome of the FDA review by the December 26, 2024 PDUFA date.
- Niktimvo Launch Execution: Monitor the actual launch timeline and initial sales uptake in Q1 2025.
- Cash Burn Rate: Assess whether the $350 million Royalty Pharma infusion (received Nov 2024) extends the runway sufficiently to reach profitability or further financing needs.
- Clinical Data Readouts: Review the Q4 2024 topline data for revumenib in mNPM1 AML and the ASH 2024 presentation data for KMT2Ar acute leukemia.
- Collaboration Terms: Confirm the status of the Incyte collaboration regarding cost-sharing and commercialization responsibilities for Niktimvo.